Journal article
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
J Grebely, ST Pham, GV Matthews, K Petoumenos, RA Bull, B Yeung, W Rawlinson, J Kaldor, A Lloyd, M Hellard, GJ Dore, PA White
Hepatology | WILEY | Published : 2012
DOI: 10.1002/hep.24754
Abstract
The purpose of the study was to evaluate reinfection and superinfection during treatment for recent hepatitis C virus (HCV). The Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of the natural history and treatment of recent HCV. Reinfection and superinfection were defined by detection of infection with an HCV strain distinct from the primary strain (using reverse-transcription polymerase chain reaction [RT-PCR] and subtype-specific nested RT-PCR assays) in the setting of spontaneous or treatment-induced viral suppression (one HCV RNA 10 IU/mL from enrollment to week 12). Among 163 patients, 111 were treated, 79% (88 of 111) had treatment-induced viral suppression, and 6..
View full abstractGrants
Awarded by National Institute on Drug Abuse
Funding Acknowledgements
This study was funded by the National Institutes of Health grant RO1 DA 15999-01. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. Roche Pharmaceuticals supplied financial support for pegylated IFN-alfa-2a/ribavirin. STP was supported by a University International Postgraduate Award. GD and AL were supported by National Health and Medical Research Council Practitioner Research Fellowships. MH was supported by a National Health and Medical Research Council Career Development Award and a VicHealth Senior Research Fellowship. JK and RB were supported by National Health and Medical Research Council Research Fellowships.